OncoSil Medical Limited Overview
OncoSil Medical is a single-product, early-commercial-stage Australian medical device company in interventional oncology. Its OncoSil™ device is a Class III, single-use brachytherapy implant. It places phosphorus-32 (³²P) microparticles directly into pancreatic tumours under endoscopic ultrasound (EUS) guidance, alongside chemotherapy. The device has CE Mark/MDR certification for unresectable locally advanced pancreatic cancer (LAPC) with gemcitabine-based chemotherapy and is approved in more than 30 countries. Australian TGA approval followed in May 2026, and US FDA Humanitarian Device Exemption (HDE) approval for distal cholangiocarcinoma (dCCA) followed on 17 August 2026. Revenue is still small (A$1.68m in FY2026, up 43.9%). The company remains loss-making (FY2026 net loss A$10.86m) and depends on equity markets, as reflected in the going-concern material uncertainty. The investment case turns on three things: converting a growing clinical evidence base (TRIPP-FFX, OSPREY, PANCOSIL, and a G-BA trial in Germany) into reimbursed, routine use; extending the label to FOLFIRINOX and percutaneous delivery; and executing launches in the US and Australia in 1H CY2027.
Company's own description (FY2026 Annual Report, Directors' Report). The Group describes its principal activities as "the development and commercialisation of its lead product candidate, the OncoSil™ localised radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma." In the Review of Operations it describes itself as "an ASX-listed medical device company which has developed a breakthrough implantable radiation (brachytherapy) device for patients with pancreatic cancer." ASX announcement boilerplate from 2026 calls it "a global medical device company focused on Interventional Oncology."
What the product does. OncoSil™ consists of ³²P microparticles suspended in a specially formulated diluent. A gastroenterologist or endoscopist implants it into the pancreatic tumour using a fine needle under EUS guidance, usually after induction chemotherapy. ³²P emits pure beta radiation over a very short path length. This delivers a high local dose while sparing nearby organs. The company points to a June 2026 peer-reviewed publication that verified strong localisation of the radiation in the pancreas.
Clinical rationale. About a third of pancreatic cancers present as locally advanced, unresectable disease. In these patients, encasement of blood vessels prevents surgery and systemic chemotherapy alone gives limited local control. OncoSil aims to:
-
improve local disease control;
-
downstage selected patients to surgical resection; and
-
extend survival.
All of this is intended to work without the multi-session hospital visits that external radiotherapy such as SBRT requires.
Business model and revenue model.
Product sales, 100%: All revenue (A$1,684,978 in FY2026) comes from sales of the OncoSil device. Revenue is recognised at a point in time, when the procedure has been performed and the device used on the patient (FY2026 Annual Report, Note 5). There is no service, subscription or licensing revenue.
Channel mix: Hybrid model. The company sells directly in core European markets through OncoSil Medical Europe GmbH (Germany, Spain, Italy, the UK, Austria, Portugal and others). It uses exclusive distributors in peripheral markets: EDH Nuclear in Türkiye, Al Zahrawi Medical Supplies in the GCC including Saudi Arabia, Femto Trade in Egypt and CardiRad in the Nordics.
Other income: The Australian R&D Tax Incentive (RDTI) is a material non-revenue inflow: A$3.40m recognised in FY2026 and A$1.84m cash received.
Value chain position. OncoSil is the regulatory manufacturer and brand owner. Upstream, it buys microparticle precursors and radio-activation services. Historically it relied on contract nuclear manufacturing in Europe. It is now moving to a proprietary process in Sydney with Cyclotek, after a manufacturing validation programme of more than 50 validation doses and about A$2.1m of specialised equipment (ASX, 13 Jul 2026). Downstream, it sells to hospitals, which recover costs through national or regional reimbursement schemes. Examples are Germany's NUB innovation funding, Italian regional procurement and Saudi reimbursement for nationals.
Customer types. Public and private hospitals, mainly university or tertiary oncology centres with interventional endoscopy (EUS) capability. The FY2026 Annual Report notes no customer exceeded 10% of revenue. The company cites 28 commercially active treatment centres at Q3 FY2026, up 56% year on year (Quartr summary of the Q3 FY2026 quarterly).
End-markets served. Oncology, specifically:
-
unresectable LAPC (CE Mark, TGA);
-
unresectable, non-metastatic dCCA (US HDE).
Pipeline indications are FOLFIRINOX combination (CE Mark extension submission planned for 2H CY2026), percutaneous CT-guided delivery by interventional radiologists (submission planned for 2H CY2026) and repeat treatment (PULSE study).
Independent characterisation. OncoSil is best understood as a pre-scale, single-asset medtech moving from "approved but under-adopted" to "commercially reimbursed." Unit economics are still negative. Cost of goods (A$2.36m) exceeded revenue (A$1.68m) in FY2026, because of low volumes, contract manufacturing costs and radioisotope logistics. The Sydney manufacturing transition is therefore central to any path to positive gross margin. The model resembles the early history of Sirtex Medical (SIR-Spheres), whose former executives now lead OncoSil: CEO Nigel Lange was Sirtex's Group Chief Commercial Officer, and Chair Thomas Duthy ran Sirtex's corporate development and investor relations. The playbook follows that precedent: build Key Opinion Leader (KOL) evidence, win reimbursement in Germany and expand centre by centre.
Strategy
Stated strategy themes (FY2026 Chairman's letter and CEO's report).
-
"Clinical momentum converting to commercial outcomes." Use TRIPP-FFX, OSPREY, PANCOSIL and independent data (Royal Adelaide SBRT comparison) to build physician confidence.
-
"Germany: The pivotal market." The G-BA-sponsored study (starting 2H CY2026) could unlock reimbursement across Germany's public hospital system. Germany has about 20,000 new pancreatic cancer cases a year, with 2,000–3,000 addressable patients, and its decisions are referenced by other European states.
-
Label expansion. FOLFIRINOX combination and percutaneous delivery to broaden eligible patients and the specialist user base.
-
New markets. US launch (HDE, dCCA) and Australian launch (TGA) in 1H CY2027; Saudi Arabia via Al Zahrawi.
-
Manufacturing sovereignty and margin. Complete the Macquarie Park/Cyclotek facility to cut COGS, improve gross margin and add supply resilience.
-
Capital discipline. A$3.4–3.9m of annualised cost savings from FY2027; R&D outflows to decline from Q2 FY2027; equity-based pay for the board and CEO.
Initiatives in the last 24 months
Guidance and targets.
-
Management previously targeted cash-flow breakeven by H2 CY2026 (May 2025 raise announcement). This has not been achieved: FY2026 operating cash outflow was A$10.5m.
-
Current guidance is qualitative: US and Australian launches in 1H CY2027, regulatory filings in 2H CY2026, G-BA trial commencement, manufacturing start-up, and declining R&D outflows.
-
No quantitative revenue or earnings guidance has been issued.
Products & Services
The company has one commercial product. Each approved indication, delivery method and development extension is catalogued separately below.
The device holds breakthrough device designation in the EU, UK and US (company descriptions, 2025).
Product Portfolio
| Offering | Description | Key specifications / capabilities | Target customer | Status / year | Pricing |
|---|---|---|---|---|---|
OncoSil™ device — LAPC with gemcitabine-based chemotherapy (EU/UK) | Single-use brachytherapy device: ³²P microparticles in diluent, implanted intratumourally under EUS guidance | Pure beta emitter; highly localised dose (localisation verified in a June 2026 publication). One-time procedure after induction chemotherapy. Supplied sterile, single patient. | EUS endoscopists / interventional GI at tertiary oncology centres | CE Mark (circa 2020); EU MDR certification Jan 2025 (BSI); UKCA renewed without post-market restrictions (Jan 2025) | Per-dose hospital price not disclosed. Germany: hospital-negotiated NUB fees. |
OncoSil™ — Australia (TGA) | Same device, ARTG-listed | For unresectable LAPC with gemcitabine-based chemotherapy | Australian public/private hospitals (about 4,350 new pancreatic cancer cases a year) | Approved 20 May 2026; launch targeted 1H CY2027 | — |
OncoSil™ — USA (FDA HDE), dCCA | Humanitarian Device Exemption | Unresectable (locally advanced and/or unfit for surgery), non-metastatic dCCA, as an adjunct to systemic therapy | US specialist hepatobiliary/GI oncology centres; about 1,000 eligible patients a year | Approved 17 Aug 2026; launch targeted 1H CY2027 | Company cites an A$80m US TAM, implying about A$80k per treatment (derived). HDE pricing limits may apply. |
OncoSil™ — Middle East / other CE-recognising markets | Distributor-led sales | Same specification | Hospitals via exclusive distributors | Approved in more than 30 countries, including Türkiye, Israel, Hong Kong, Singapore, Malaysia, New Zealand and Switzerland. Saudi SFDA approval Jul 2026, with full reimbursement for Saudi nationals. | Distributor transfer pricing not disclosed |
Percutaneous (CT-guided) delivery — pipeline | Alternative to EUS implantation, delivered by interventional radiologists | Supported by PANCOSIL (20 patients, Amsterdam UMC); safe and feasible (CIRSE 2025) | Interventional radiology / interventional oncology | Regulatory submission targeted 2H CY2026 | — |
FOLFIRINOX combination label — pipeline | Label extension to today's standard of care | TRIPP-FFX: 82.2% local disease control rate at 16 weeks (95% CI 68–92%); median OS 18.3 months with OncoSil + FOLFIRINOX | Medical oncologists, Europe | CE Mark extension submission targeted 2H CY2026 | — |
Repeat treatment — pipeline | Second OncoSil implantation in non-progressive LAPC after induction chemotherapy | PULSE Phase II: 120 patients, 5 centres, 1:1 randomised; devices supplied in kind | Academic PALACROS centres | Study start under PALACROS (announced 2 Jul 2026) | — |
US pancreatic cancer indication — long-term | Premarket Approval (PMA) route | A "Global Pivotal Clinical Study" to support a future US premarket application for pancreatic cancer | US market | Planned; no timeline disclosed | — |
Support services | Physician training, proctoring, KOL advisory boards (e.g., London Advisory Board, Jan 2025), OSPREY registry | Not separately monetised | Treating centres | Ongoing | Bundled |
“—” = not publicly disclosed.
Financial Narrative
Income statement: notes and sources
Sources: FY2026 AR income statement and 5-year table; FY2025 4E. FY2022–23 cost of revenue is from Kalkine (secondary). Operating loss (derived) = pre-tax loss + finance costs − interest revenue. EBITDA (derived) = operating loss + depreciation (FY2026 A$59.5k; FY2025 A$35.7k). No amortisation; no capitalised development.
Margins and growth
Revenue CAGR: FY2022–FY2026 (4 years) about 64.2% (derived: 1,685.0 / 231.8). FY2024–FY2026 (2 years) about 80.6%.
Commentary. Revenue has compounded quickly from a tiny base. The inflection in FY2025 (+126.6%) followed MDR certification in January 2025 and German NUB eligibility. Growth continued in FY2026 (+43.9%; unit sales +53%) with new launches in Portugal, Germany and the UK. Gross margin is still negative but improving sharply, from −92.5% to −39.9%. This reflects fixed manufacturing and isotope logistics costs being spread over more doses. Cost of sales rose only 4.6% while revenue rose 43.9%. The FY2026 loss narrowed 28.1% to A$10.86m. The main driver was a jump in recognised RDTI income (A$3.40m vs A$0.36m), together with lower consulting, legal and administrative costs (−A$1.59m combined). R&D expense rose 30% to A$5.47m as TRIPP-FFX and PANCOSIL closed out. Excluding RDTI, the underlying operating loss was about A$14.4m in FY2026 vs A$15.6m in FY2025 (derived). Underlying cost discipline is therefore improving more slowly than the headline suggests. Management has identified A$3.4–3.9m of annualised savings from FY2027 and expects R&D cash outflows to fall from Q2 FY2027.
Balance sheet
Sources: FY2026 AR (FY2025–26 and the 1 Jul 2024 equity balance); Kalkine and moomoo (secondary) for FY2022–24 cash, receivables, PP&E, net debt and liabilities. FY2023 and FY2024 total assets are derived as equity/NTA plus liabilities (approximate).
Commentary. There is no financial debt. The only debt-like items are small lease liabilities (A$14.8k). The balance sheet consists of cash plus receivables, and the receivables likely include accrued RDTI (FY2026 RDTI recognised A$3.40m vs cash received A$1.84m). Equity of A$5.0m against accumulated losses of A$117.3m shows the scale of capital consumed since inception, about A$105m of issued capital. Payables rose to A$5.20m, including A$679k owed to Cyclotek. With current assets of A$9.38m, liquidity is adequate but tight. Pro forma cash after the September 2026 raise is A$12.1m (company estimate).
Cash flow
Sources: FY2026 AR cash flow statement; InvestSMART (secondary) for FY2024 operating and financing cash flows.
Commentary. Customer receipts rose 179% to A$2.1m. This exceeded recognised revenue, implying collection of prior-period receivables. Cash burn (operating cash flow) improved 13% to A$10.5m. Reported capex is negligible because the manufacturing equipment (about A$2.1m) appears to be funded through supplier payables and accruals: PP&E rose by A$558k while the cash outflow was only A$1.5k. Expect higher cash capex as those payables are settled. FY2026 average quarterly burn was about A$2.6m. The Q4 FY2026 net operating outflow was A$2.6m (Appendix 4C, 30 Jul 2026), which implies roughly 4–5 quarters of runway on pro forma cash of A$12.1m before cost savings and US/Australian launch costs.
Ratios
Net debt/EBITDA is shown as a positive ratio because both net debt (net cash) and EBITDA are negative; it is not economically meaningful. ROIC and interest coverage are not meaningful (no invested debt capital; EBIT is negative). The cash conversion cycle is not meaningful because receivables are dominated by RDTI and inventory is negligible (A$5.6k in FY2026).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue OncoSil device (AUD K) | 516.6 | 1,170.8 | 1,685.0 |
YoY revenue growth (%) | 40.5 | 126.6 | 43.9 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Segment pre-tax loss (AUD K) | -11,913.6 | -15,099.8 | -10,860.1 |
Segment net margin (%) | -2,306.1 | -1,289.7 | -644.5 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Sales revenue (AUD K) | 231.8 | 367.7 | 516.6 | 1,170.8 | 1,685.0 |
Total revenue and other income incl. RDTI and interest (AUD K) | 1,073.5 | 1,530.0 | 1,631.9 | 1,626.2 | 5,228.7 |
Cost of sales (AUD K) | 970 | 1,590 | — | 2,253.6 | 2,357.3 |
Gross profit (AUD K) | -738 | -1,222 | — | -1,082.8 | -672.3 |
R&D expense (AUD K) | — | — | — | 4,210.9 | 5,472.3 |
Employee benefits expense (AUD K) | — | — | — | 4,896.7 | 4,958.2 |
RDTI other income (AUD K) | — | — | — | 364.5 | 3,404.1 |
Operating loss incl. RDTI (AUD K) (derived) | — | — | — | -15,189.8 | -10,982.9 |
EBITDA (AUD K) (derived) | — | — | — | -15,154.1 | -10,923.4 |
Pre-tax loss (AUD K) | -10,726.7 | -11,342.9 | -11,913.6 | -15,099.8 | -10,860.1 |
Net loss (AUD K) | -10,726.7 | -11,342.9 | -11,913.6 | -15,099.8 | -10,860.1 |
Basic EPS (A$ cents, post-consolidation) | -529.21 | -401.66 | -215.60 | -138.17 | -47.95 |
Diluted EPS (A$ cents) | -529.21 | -401.66 | -215.60 | -138.17 | -47.95 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth YoY (%) | 8.8 | 58.6 | 40.5 | 126.6 | 43.9 |
Gross margin (%) | -318 | -332 | — | -92.5 | -39.9 |
Operating margin (%) (derived) | — | — | — | -1,297.4 | -651.8 |
EBITDA margin (%) (derived) | — | — | — | -1,294.3 | -648.3 |
Net margin (%) | -4,627 | -3,085 | -2,306 | -1,289.7 | -644.5 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash & equivalents (AUD K) | 11,280 | 9,390 | 4,501.4 | 5,109.7 | 6,475.9 |
Trade & other receivables (AUD K) | 910 | 1,290 | 1,350 | 1,204.5 | 2,443.7 |
Total current assets (AUD K) | — | — | — | 6,723.9 | 9,381.3 |
Plant & equipment (AUD K) | 324.9 | 239.3 | 112.8 | 359.0 | 916.7 |
Total assets (AUD K) | — | 11,470 | 6,506 | 7,148.1 | 10,311.3 |
Trade & other payables (AUD K) | — | — | — | 3,855.6 | 5,196.2 |
Total debt incl. leases (AUD K) | — | — | — | 69.9 | 14.8 |
Short-term debt / leases (AUD K) | — | — | — | 53.7 | 14.8 |
Long-term debt / leases (AUD K) | — | — | — | 16.2 | 0 |
Net debt (negative = net cash) (AUD K) | -10,976 | -9,223 | -4,431 | -5,039.8 | -6,461.1 |
Total liabilities (AUD K) | 1,910 | 1,590 | 1,770 | 4,044.6 | 5,314.9 |
Total equity (AUD K) | — | — | 4,736.4 | 3,103.5 | 4,996.4 |
Net tangible assets (AUD K) | 11,160 | 9,880 | — | 3,108.1 | 4,997.9 |
Goodwill & intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) (derived) | — | — | — | 2,701.7 | 4,074.0 |
Accumulated losses (AUD K) | — | — | -92,781.2 | -107,457.8 | -117,322.8 |
Issued capital (AUD K) | — | — | 90,094.0 | 96,425.1 | 105,455.7 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Receipts from customers (AUD K) | — | — | — | 758.5 | 2,115.0 |
RDTI cash received (AUD K) | — | — | — | 1,050.9 | 1,840.1 |
Operating cash flow (AUD K) | — | — | -11,130 | -12,062.3 | -10,472.4 |
Capex PP&E (AUD K) | — | — | — | -15.0 | -1.5 |
Free cash flow (AUD K) (derived) | — | — | — | -12,077.3 | -10,473.9 |
Equity issued net incl. options (AUD K) | — | — | 6,000 | 12,780.6 | 11,916.9 |
Net financing cash flow (AUD K) | — | — | 6,000 | 12,726.7 | 11,861.7 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2025 | FY2026 |
|---|---|---|
ROE (%) (derived, avg equity) | -385.2 | -268.2 |
ROA (%) (derived, avg assets) | -221.2 | -124.4 |
Current ratio (x) | 1.67 | 1.77 |
Debt / equity (x) | 0.02 | 0.00 |
Net debt / EBITDA (x) | 0.33 | 0.59 |
Asset turnover (x) (derived) | 0.17 | 0.19 |
Revenue by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia revenue (AUD K) | — | 15.0 | 91.4 |
Europe revenue (AUD K) | — | 869.6 | 1,404.5 |
Middle East and United Kingdom revenue (AUD K) | — | 286.2 | 189.1 |
Total revenue (AUD K) | 516.6 | 1,170.8 | 1,685.0 |
Revenue by Region (%)
| Region (%) | FY2026 YoY growth (%) | FY2026 share of revenue (%) |
|---|---|---|
Australia | 509.1 | 5.4 |
Europe | 61.5 | 83.4 |
Middle East and United Kingdom | -33.9 | 11.2 |
Share Price and Share Count (m)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 13.00 | 4.80 | 1.60 | 1.20 | 0.71 |
Shares on issue at 30 June (m) | — | — | — | 14.22 | 30.89 |
Market cap at 30 June (AUD Mn, InvestSMART) | — | — | 13 | 17 | 22 |
Valuation Multiples
| Multiple | OncoSil | Comment |
|---|---|---|
Market cap | ~A$38m | ~36.7m shares × ~A$1.05 |
Enterprise value | ~A$26m | Less pro forma cash of A$12.1m; no debt |
EV / Sales (FY2026) | ~15.7x | On A$1.685m revenue |
P/E | n/m | Loss-making |
EV/EBITDA | n/m | Negative EBITDA |
P/B (reported FY2026 equity A$5.0m) | ~7.6x | ~3.6x on pro forma equity of about A$10.6m (derived) |
Share Price & Returns
| Date | Raise | Price (A$, post-consolidation basis) |
|---|---|---|
Oct–Nov 2024 | Up to A$8m (placement + SPP) | ~A$2.80 equivalent (pre-consolidation ~A$0.007) |
May–Jul 2025 | A$8.7m (placement + SPP) | A$1.20 equivalent (A$0.003 × 400) |
Jul 2025 | A$3.5m placement | A$1.20 |
Feb–Mar 2026 | A$8.0m (placement + entitlement offer) | A$0.68 |
Sep 2026 | A$4.0m placement + A$1.6m options | A$1.00 / A$0.90 |
Analyst Conclusions
Management guidance (FY2026 AR and Sep 2026 announcement)
-
US commercial launch (HDE, dCCA) and Australian launch (TGA, LAPC) in 1H CY2027.
-
Two European regulatory filings in 1H FY2027: FOLFIRINOX CE Mark extension and percutaneous delivery.
-
G-BA-funded trial in Germany to commence (2H CY2026).
-
Start of commercial manufacturing at the OncoSil/Cyclotek facility in Sydney, subject to approval.
-
Annualised cost savings of A$3.4–3.9m from FY2027; R&D cash outflows declining from Q2 FY2027.
-
No quantitative revenue, margin or breakeven guidance is current. The earlier "cash-flow breakeven by H2 CY2026" target is effectively superseded.
Consensus growth expectations. Not publicly available. Recent run-rates point to continued 40–60% revenue growth in Europe (FY2026 +43.9%; Q3 FY2026 +49%). US and Australian contributions are unlikely to be material before 2H FY2027.
Bull case
-
Dual approvals de-risk the platform. FDA HDE (a rare achievement for an ASX device company) and TGA approval open two new markets: an A$80m US dCCA TAM plus the Australian home market. The HDE also creates a US clinical base for a future pancreatic PMA.
-
German reimbursement could be the inflection. A positive G-BA pathway would unlock 2,000–3,000 addressable patients and set a reference for other EU systems. Even 10% penetration would be a multiple of current volumes.
-
Operating leverage is visible. COGS was flat while revenue grew 44%. Sydney manufacturing, A$3.4–3.9m of cost savings and falling trial spend could narrow cash burn sharply, while the registry and investigator-led evidence base keeps growing.
Bear case
-
Funding treadmill. Pro forma cash of A$12.1m against roughly A$10m+ annual burn, plus launch costs in two new countries, means more dilution is likely in 2027. There are 27m options outstanding and the going-concern uncertainty remains.
-
Commercial scale remains unproven. After years on the market in Europe, revenue is A$1.7m with negative gross margin. HDE commercial constraints (patient cap, potential profit limits, IRB requirements) may make the US more strategic than lucrative near term.
-
Evidence gap. No randomised, OS-powered superiority trial exists. TRIPP-FFX was non-comparative, and registry or retrospective data may not secure guideline inclusion or HTA approval, while alternatives (SBRT, TTFields, EUS-RFA) keep advancing.
Key catalysts and monitorables (next 12 months)
Concluding analyst verdict
OncoSil Medical enters FY2027 in the strongest strategic position of its 21-year listed history, and with one of its weakest-looking income statements relative to that position. Regulatory risk, which dominated the equity story for a decade, has largely been retired. The company has an MDR certificate, TGA inclusion, an FDA HDE and Saudi approval. The device is also accumulating credible real-world survival data from independent European and Australian investigators. Those are hard-won assets for a company with a market capitalisation of about A$38m.
What remains is commercial and financial execution risk, and that risk is substantial. FY2026 revenue of A$1.68m against cost of sales of A$2.36m shows the business does not yet earn a positive gross margin. Operating cash burn of A$10.5m against pro forma cash of A$12.1m implies another equity raise within roughly 12 months unless burn falls quickly. The auditor's going-concern emphasis is warranted. The earlier breakeven target for H2 CY2026 was missed, which should temper reliance on management timetables.
The investment debate therefore comes down to three measurable variables:
-
the gross-margin step-change from Sydney manufacturing;
-
the pace of German adoption ahead of and through the G-BA trial; and
-
the real economics of the US HDE launch, including any profit constraints under the HDE framework.
The September 2026 placement at a premium, funded by the three largest institutional holders, is a meaningful signal of informed conviction. Even so, the dilution history and a 27m-option overhang cap per-share upside in the near term.
Verdict: a high-risk, catalyst-rich micro-cap. The risk/reward is asymmetric if German reimbursement and margin improvement arrive together in FY2027. It is unattractive if commercial volumes stall and funding must be raised at a discount. Base-case stance: speculative/neutral, pending evidence of positive gross margin and quarterly receipts above A$1m.
Sources: OncoSil Medical FY2026 Appendix 4E & Annual Report (28 Aug 2026); FY2025 Appendix 4E (Aug 2025); FY2023 Annual Report (31 Aug 2023); ASX announcements of 30 Jan 2025, 25 Feb 2025, 29 Apr 2025, 26 May 2025, 2 Jul 2026, 13 Jul 2026, 20 Jul 2026, 30 Jul 2026, 17 Aug 2026, 7 Sep 2026 and 8 Sep 2026; prospectus of 3 Feb 2026; ClinicalTrials.gov NCT05466799; pSivida SEC filings (2005–2008). Secondary sources: InvestSMART/Morningstar, Kalkine, moomoo, Stoxray, TipRanks, Biotech Dispatch, Biotech Daily, Medical Device Network, BioSpectrum Asia, Quartr, Stockhead, roic.ai. Derived figures are analyst calculations from reported line items. Competitor figures are approximate and should be verified against those companies' filings.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Appointed | Background | Education | Committees |
|---|---|---|---|---|---|
Dr Thomas Duthy | Non-Executive Chairman | NED 11 Jul 2025; Chair 1 Oct 2025 | 22+ years in financial markets and healthcare corporate development. Founder of Nemean Group. Former Head of Corporate Development & IR at Sirtex Medical (A$1.9bn sale to China Grand Pharma/CDH). Advised on the Ellex/Lumibird, Limeade/WebMD and Pivotal Systems transactions. Recent former directorships: Arovella, Neurotech, Neurizon, Invex. | PhD (University of Adelaide), MBA (Deakin) | NRC, ARC (member) |
Nigel Lange | CEO & Managing Director | Joined May 2020; CEO agreement from 21 Jan 2021 | 40+ years in medical devices. At Sirtex from 2003: CEO Europe (300+ centres), Group CCO from 2017, interim Group CEO and interim CEO APAC. | BA, B.Comm | NRC, ARC (member) |
Lel Smits | Non-Executive Director | Mid-Jan 2025 | Managing Director of The Stock Network (investor media). Australian Shareholders' Association director 2021–2026. Former broadcast finance journalist. | AICD graduate; Dip. IR (AIRA); MA Journalism (UTS); BMedia, BA (Adelaide) | NRC, ARC (member) |
Douglas Cubbin | Former Chairman | Resigned as Chair 1 Oct 2025; retired 19 Nov 2025 | Also NED of Cyclotek (related party) | — | — |
Dr Gabriel Liberatore | Former NED | Resigned 11 Jul 2025 (personal reasons) | — | — | — |
Executive Leadership Team
| Name | Title | Tenure | Notes |
|---|---|---|---|
Nigel Lange | CEO & MD | CEO since Jan 2021 | Base salary €260,000 plus about €25,000 in benefits. STI up to 35%, LTI up to 35%. Six months' notice. |
Shelley Steyn | CFO | Since 5 May 2025 | Base A$270,000 plus super. STI up to 25%. 12 weeks' notice. |
Dr Ralph Peters | Chief Medical Officer (per Kalkine) | — | Secondary source only |
David Turner | Head of Medical Affairs (per Kalkine) | — | Secondary source only |
Rachel Duggan | EMEA Sales Director | Since Oct 2024 | ASX announcement, 29 Oct 2024 |
Directors' Remuneration
| Person | Cash salary/fees | Cash bonus | Non-monetary | Super | LSL | Options | Shares | Perf. rights | Total |
|---|---|---|---|---|---|---|---|---|---|
Dr Thomas Duthy (Chair) | 66,300 | 0 | 0 | 0 | 0 | 86,712 | 45,200 | 0 | 198,212 |
Douglas Cubbin | 30,085 | 0 | 0 | 3,610 | 0 | 3,952 | 0 | 0 | 37,647 |
Lel Smits | 18,333 | 0 | 0 | 2,200 | 0 | 2,000 | 33,434 | 0 | 55,967 |
Gabriel Liberatore | 4,129 | 0 | 0 | 496 | 0 | 184 | 0 | 0 | 4,809 |
Nigel Lange (CEO) | 428,319 | 46,929 | 47,711 | 0 | 0 | 53,123 | 5,325 | 156,406 | 737,813 |
Shelley Steyn (CFO) | 270,000 | 57,400 | 0 | 30,000 | 669 | 418 | 0 | 0 | 358,487 |
Total KMP | 817,166 | 104,329 | 47,711 | 36,306 | 669 | 146,389 | 83,959 | 156,406 | 1,392,935 |
Major Shareholders
| Holder | Stake | Source / note |
|---|---|---|
Pengana Capital Group / Pengana High Conviction Equities Fund | Substantial (>5%); among the three largest holders | Cornerstone in the May 2025, Feb 2026 and Sep 2026 raises. Exact % not publicly verified. |
Regal Partners / Regal Funds Management | Substantial; among the three largest | Cornerstone Feb 2026; Sep 2026 placement |
Australian Ethical Investment | Among the three largest | Sep 2026 placement |
Washington H. Soul Pattinson (SOL) | Lodged a "change in substantial holding" on 18 Jun 2025 | — |
Directors & KMP combined | 313,000 shares at 30 Jun 2026, about 1.0% of 30.9m shares | FY2026 AR. Plus 644,121 options and 234,925 performance rights. |
Competitive Landscape
Key Competitors
| Competitor | Offering | Segment overlap | Relative positioning vs OncoSil |
|---|---|---|---|
Elekta (Sweden) | Linear accelerators, Unity MR-Linac (SBRT/MR-guided RT) | External radiotherapy for LAPC | Entrenched installed base; non-invasive but needs 5+ fractions. OncoSil cites superior OS vs SBRT in the Adelaide data. |
Siemens Healthineers / Varian | TrueBeam/Halcyon linacs, SBRT | External RT | Dominant RT vendor; same dynamic as Elekta |
Accuray (US) | CyberKnife SBRT | External RT | Niche SBRT |
AngioDynamics (US) | NanoKnife irreversible electroporation (IRE) | Local ablation of LAPC | Open or laparoscopic surgical procedure; US-focused; mixed evidence |
Novocure (US/Jersey) | Tumour Treating Fields, LAPC (PANOVA-3 trial) | Local-regional LAPC therapy | Well-funded; wearable, non-invasive. Regulatory status in pancreatic cancer to be verified. |
Alpha Tau Medical (Israel) | Alpha DaRT (radium-224 intratumoural alpha emitter) | Intratumoural brachytherapy, pancreas trials | Closest technology analogue; pre-commercial in pancreas |
Perspective Therapeutics / Isoray (US) | Cs-131 seed brachytherapy | Brachytherapy | Focus is other tumour types |
Sirtex Medical (CDH/China Grand Pharma) | SIR-Spheres Y-90 | Liver-directed radioembolisation; potential cholangiocarcinoma overlap | Global commercial infrastructure; comparable business model |
Boston Scientific | TheraSphere Y-90; EUS-RFA accessories | Liver/biliary radiotherapy; EUS ecosystem | Scale player; could be competitor or acquirer (speculative) |
Taewoong Medical / STARmed | EUS-guided radiofrequency ablation (EUS-RFA) | EUS-delivered local ablation of pancreatic tumours | Low-cost, same EUS channel; emerging data |
Ipsen | Onivyde (NALIRIFOX) | Systemic therapy | Complementary or competing for the treatment budget |
AstraZeneca / Merck | Durvalumab / pembrolizumab + gem/cis in biliary tract cancer | Systemic dCCA standard of care | OncoSil's HDE is "adjunct to systemic therapy", so complementary |
Peer Comparison FY2026
| Metric | OncoSil (FY2026) | Novocure (CY2024) | AngioDynamics (FY2025, May YE) |
|---|---|---|---|
Revenue | A$1.7m | ~US$605m | ~US$290m |
Revenue growth | +43.9% | ~+19% | low single digit |
Gross margin | −39.9% | ~75–80% | ~50–55% |
Net margin | −644.5% | negative | negative |
R&D intensity (% of revenue) | ~325% | ~35% | ~10% |
Recent Developments
--



